Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET
DALLAS--(BUSINESS WIRE)--Oct. 21, 2021--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit.
Conference Details:
|
Event:
|
|
Jefferies Gene Therapy & Editing Summit
|
|
Date:
|
|
Thursday, October 28, 2021
|
|
Time:
|
|
11:00 am ET
|
|
Format:
|
|
Fireside Chat
|
|
Participants:
|
|
RA Session II, President, Founder and Chief Executive Officer
|
|
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
|
|
|
|
Kamran Alam, Chief Financial Officer
|
|
|
|
Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations
|
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005262/en/
Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com
Source: Taysha Gene Therapies, Inc.
